Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3381-3400 of 3,900 trials

HER2-Positive Breast Cancer: New Treatment Without Chemotherapy

We are studying a combination of trastuzumab, pertuzumab, and tucatinib for patients with stage II-III HER2-positive breast cancer. The goal is to evaluate the safety and initial effectiveness of this chemotherapy-free approach.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Linaprazan Glurate: Interaction with Antibiotic

We are investigating how a new medication affects the way an approved antibiotic works in healthy individuals. This study may help us understand better drug interactions.

Helicobacter Pylori InfectionGastroesophageal Reflux Disease (GERD)3-6 monthsSafety phase (I)GastroenterologyInternal Medicine

Heart Attack Treatment: Evolocumab vs. Standard Care

We are studying whether the medication evolocumab can better prevent heart-related problems compared to standard treatments for patients who have recently had a heart attack. This trial focuses on improving cholesterol control and reducing hospitalizations.

Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Pancreatic Cancer: Napabucasin with Chemotherapy

We are studying how well Napabucasin works with chemotherapy for patients with metastatic pancreatic cancer after previous treatments have failed. The goal is to see if this combination improves survival and quality of life compared to standard care.

Metastatic Pancreatic CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Plozasiran for Severe Hypertriglyceridemia: SHASTA-5 Study

We are studying whether plozasiran can help adults with severe hypertriglyceridemia reduce their triglyceride levels and lower the risk of acute pancreatitis. The trial also looks at the treatment's safety and how it affects patients' overall health.

High Triglycerides>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

Hereditary Angioedema: BW-20805 Study

We are investigating the effects and safety of BW-20805 in adults with hereditary angioedema. The study aims to see if it can help reduce the number of HAE attacks.

Hereditary Angioedema1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInternal Medicine

Ketamine Therapy for Obsessive-Compulsive Disorder

We are studying whether ketamine can effectively reduce symptoms of obsessive-compulsive disorder. This trial will help us understand its impact on mental function during stressful situations.

Obsessive Compulsive Disorder (OCD)≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

Growth Hormone and Liver Fat Metabolism Study

We are investigating how growth hormone influences fat processing in the liver of healthy adults. Additionally, we will explore its effects in patients with acromegaly to understand fat secretion better.

AcromegalyHealthy Participants≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyHepatology

Prolonged Grief Disorder: PEX010 Treatment

We are testing a new treatment called PEX010 for people experiencing prolonged grief disorder. The study aims to see if it can significantly reduce grief symptoms and explore the effects of self-touch.

Prolonged Grief Disorder≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Cefiderocol in Peritoneal Dialysis Patients

We are studying how cefiderocol is processed in the body of patients receiving peritoneal dialysis. This research aims to improve treatment options for infections in these patients.

Patients Undergoing Peritoneal Dialysis>2 yearsSafety phase (I)Infectious DiseasesNephrology

Non-Small Cell Lung Cancer: Drug Sequencing Study

We are investigating the best order to use two medications for patients with advanced non-small cell lung cancer that has specific mutations. This study aims to see which treatment sequence may improve outcomes for these patients.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Metastatic Non-Small-Cell Lung Cancer: Tedopi Combinations

We are studying the effects of Tedopi combined with either docetaxel or nivolumab in patients with advanced lung cancer who have not responded to previous treatments. This trial aims to see if these combinations can improve survival rates and overall health.

Metastatic Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Dopamine Changes in Depression: Escitalopram vs. Bupropion

We are studying how rewards affect dopamine levels in the brain of people with major depressive disorder compared to healthy volunteers. This trial also looks at how two different antidepressants may influence these changes.

Major Depression>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPsychiatry

Heart Failure Treatment: Sacubitril/Valsartan vs. Ramipril

We are studying how two heart medications affect heart function in patients with ischemic heart failure. Our goal is to see which treatment better helps improve heart structure and performance.

Congestive Heart Failure1-2 yearsConfirmation phase (III)Standard MedicinesCardiologyInternal Medicine

Zinc Acexamate for Advanced Chronic Liver Disease

We are studying whether Zinc Acexamate can improve health outcomes for patients with advanced chronic liver disease. This trial compares its effects to a placebo to see if it reduces complications and improves survival.

Advanced Chronic Liver Disease>2 yearsConfirmation phase (III)Standard MedicinesHepatologyInternal Medicine

Fecal Incontinence: ICEF15 Therapy

We are testing a new treatment for fecal incontinence caused by anal sphincter weakness. The study aims to see if this therapy improves symptoms and enhances quality of life for patients.

Fecal Incontinence1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterology

Acute Myeloid Leukemia: NOPHO-DBH AML 2012 Study

We are researching new treatment options for children and adolescents with acute myeloid leukemia. The goal is to find more effective therapies while reducing side effects and improving overall outcomes.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyPediatrics

Psychiatric Disorders: Immunotherapy Study

We are testing whether immunotherapy can help patients with psychotic symptoms and autoimmune conditions when added to their ongoing psychiatric care. This study aims to improve understanding of treatment options for these patients.

Mental Disorder1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPsychiatry

Antibiotics: Single Dose Study

We are examining how a single dose of certain antibiotics is absorbed in the body of healthy volunteers. This research may help improve treatment strategies for infections.

Healthy VolunteersSafety phase (I)Infectious Diseases

Primary Plasma Cell Leukemia: New Treatment with Bortezomib and Daratumumab

We are studying a combination of medications for people with primary plasma cell leukemia to see if it improves treatment outcomes and safety. This trial will help us understand how well this new approach works compared to current treatments.

Plasma Cell Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology